Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AtheroGenics drops on diabetes data

AGIX plunged $1.04 (35%) to $1.96 on 14.6 million shares on Wednesday, as investors digested bearish comments by a Swedish researcher following a presentation of

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE